Does Sotalol Cause Weight Gain?

Sotalol can contribute to weight gain, but the effect tends to be modest and varies from person to person. As a nonselective beta-blocker, sotalol shares metabolic properties with other drugs in the class that are known to slow resting energy expenditure and promote fluid retention. That said, sotalol has some unusual characteristics that set it apart from more commonly studied beta-blockers, and the direct evidence linking it specifically to meaningful weight gain is thinner than many patients assume.

Why Beta-Blockers in General Are Linked to Weight Gain

Sotalol belongs to the beta-blocker family, a group of medications that block the effects of adrenaline on the heart and blood vessels. It is a nonselective beta-adrenoceptor antagonist, meaning it blocks both beta-1 receptors (mainly in the heart) and beta-2 receptors (found in the lungs, blood vessels, and metabolic tissue). It also prolongs cardiac repolarization independently of its beta-blocking action, which is what gives it its additional role as a class III antiarrhythmic drug.¹ Most people are prescribed sotalol to control irregular heart rhythms, particularly atrial fibrillation or ventricular tachycardia, rather than for blood pressure alone.

The weight-gain concern with beta-blockers as a class stems from a few overlapping mechanisms. One is a reduction in resting metabolic rate. Beta-2 receptors play a role in thermogenesis, the process by which your body burns calories to produce heat. When those receptors are blocked, your body burns fewer calories at rest. A study of propranolol, another nonselective beta-blocker, found that it reduced resting metabolic rate by about 9% when patients ate a normal diet.² That may not sound dramatic, but a 9% drop means your body is burning roughly 150 to 180 fewer calories per day if your baseline is around 1,800 to 2,000. Over weeks and months, that deficit adds up if eating habits stay the same.

The second factor is fatigue. Beta-blockers lower heart rate and dampen the body’s response to exertion. Many people report feeling more tired or sluggish on these medications, which can reduce both structured exercise and everyday physical activity. The third factor is fluid retention. Beta-blockers can shift how the kidneys handle sodium and water, leading to mild fluid accumulation that registers on the scale even if fat mass has not changed.

How Sotalol Compares to Other Beta-Blockers

Not all beta-blockers affect weight equally. Lipophilic (fat-soluble) beta-blockers like propranolol and metoprolol cross into the brain more easily and tend to produce more pronounced fatigue and metabolic slowing. Sotalol, by contrast, is a highly hydrophilic (water-soluble) drug. This means it stays largely in the bloodstream and does not cross the blood-brain barrier as readily. For patients, this often translates to fewer central nervous system side effects like fatigue and depression, which are some of the indirect routes through which other beta-blockers encourage weight gain.

A narrative review on antiarrhythmic drugs and obesity noted that sotalol’s pharmacokinetic properties are similar in obese and lean individuals, and that the drug appears unaffected by body weight.³ That finding matters in two directions. First, it suggests that dosing does not need to be adjusted based on body size the way some other antiarrhythmics do. Second, it implies that sotalol does not accumulate differently in fatty tissue, which could partly explain why its metabolic side-effect profile seems milder than that of fat-soluble beta-blockers.

Despite these pharmacological differences, sotalol is still a nonselective beta-blocker. It still blocks beta-2 receptors involved in metabolic rate and thermogenesis. The theoretical mechanism for weight gain exists; it is just less well-documented for sotalol specifically than for propranolol or atenolol, which have been studied more extensively in weight-related outcomes. The absence of strong direct evidence does not mean sotalol is weight-neutral. It means the research simply has not focused on this drug as closely when it comes to body composition.

Fluid Retention Versus Fat Gain

When patients notice weight gain soon after starting sotalol, the cause is more likely fluid retention than actual fat accumulation. Fat gain from a lower metabolic rate is a slow process that unfolds over months. A jump of two or three pounds in the first week or two is almost certainly water. Beta-blockers can alter kidney function in ways that lead to mild sodium and water retention, particularly at higher doses or in people who already have borderline heart or kidney function.

Research on adrenergic blockade and fluid balance has shown that beta-blockade can counteract some fluid retention caused by other drug classes. One study examining combined alpha- and beta-blockade in Raynaud’s syndrome found that fluid retention appeared with alpha-blockade alone but was absent when beta-blockade was added.⁴ This does not mean beta-blockers universally prevent fluid retention, but it illustrates that the relationship between adrenergic drugs and fluid balance is more nuanced than a simple “beta-blockers cause swelling” narrative.

If you notice ankle swelling, tighter shoes, or a quick bump on the scale within days of starting sotalol, mention it to your prescriber. Mild fluid retention sometimes resolves on its own as your body adjusts to the medication. In other cases, a low-sodium diet or a mild diuretic can manage it without needing to stop sotalol. The distinction between fluid and fat matters because the management strategies are different, and because rapid weight changes can also signal heart failure progression in the population that often takes sotalol.

How Much Weight Gain to Realistically Expect

Large-scale studies directly measuring weight change on sotalol are scarce. What we know about beta-blocker-associated weight gain in general suggests the typical amount is modest, usually in the range of two to six pounds over the first few months of treatment. Much of the data comes from studies of older beta-blockers like atenolol and metoprolol in hypertension trials. Sotalol is primarily prescribed for arrhythmias rather than blood pressure, so the patient population tends to be somewhat different, and the question has received less attention in clinical trials.

There is also an important confounder. Many people who start sotalol are doing so because they have a newly diagnosed arrhythmia like atrial fibrillation. Uncontrolled atrial fibrillation can cause symptoms like exercise intolerance, palpitations, and anxiety, all of which can suppress appetite or increase restlessness. Once the arrhythmia is controlled and the patient feels calmer and sleeps better, appetite and activity patterns may shift in ways that favor weight gain regardless of the medication itself. Disentangling the drug’s effect from the effect of simply feeling better is difficult without controlled trials, which have not been done specifically for sotalol and body weight.

For most people, sotalol is unlikely to cause dramatic weight changes. If you gain more than five to seven pounds that cannot be explained by dietary changes, that warrants a conversation with your doctor to rule out fluid overload or other metabolic shifts.

Who Might Be More Susceptible

Certain groups are more likely to notice weight-related changes on beta-blockers. People with lower baseline metabolic rates, including older adults and those who are already sedentary, have less room to absorb a metabolic slowdown without gaining weight. Women tend to have lower resting metabolic rates than men, which can amplify even a small percentage decrease. Patients with hypothyroidism, insulin resistance, or polycystic ovary syndrome may already have metabolic headwinds that beta-blockers compound.

There is also the dose factor. Sotalol is typically started at 80 mg twice daily and can be titrated up to 160 mg twice daily or higher for certain arrhythmias. Higher doses produce more profound beta-blockade, which theoretically increases the metabolic impact. If you were started on a lower dose and notice weight creeping up after an increase, the two events are likely related.

Interestingly, body weight also plays a role in how well patients stick with sotalol. One study of sotalol compliance after coronary artery bypass surgery found that patients who stopped taking the medication had markedly lower body weight than those who remained compliant.⁵ The authors did not identify weight gain as the reason for noncompliance, but the finding highlights that body weight interacts with sotalol use in ways that are not fully understood.

Practical Steps If You Are Concerned About Weight on Sotalol

The most important thing to recognize is that sotalol is not a lifestyle drug. It is prescribed for arrhythmias that carry real risks, including stroke and heart failure. Stopping it because of a few extra pounds is almost never the right trade-off. That said, managing weight proactively while on sotalol is entirely reasonable.

A few strategies that align with what we know about beta-blocker metabolism:

Track early: Weigh yourself the week before starting sotalol to establish a baseline. Continue weekly for the first two to three months. This gives you and your doctor real data rather than guesswork.
Adjust calories modestly: If beta-blockade does reduce your resting metabolic rate by something in the range of 5 to 10%, you may need to eat slightly less than before to maintain weight. For most people, that means cutting roughly 100 to 200 calories per day, the equivalent of one snack.
Stay active within limits: Sotalol lowers your maximum heart rate, so exercise feels harder at the same intensity. You may need to recalibrate expectations. Lower-intensity but longer-duration activities like walking, swimming, or cycling are often better tolerated than high-intensity interval training on a beta-blocker.
Watch sodium: Because fluid retention is the most common early contributor to scale changes, keeping sodium intake moderate can help. This does not require a drastic low-sodium diet, just awareness of high-sodium processed foods.

The propranolol study mentioned earlier found that beta-blockade did not reduce the effectiveness of calorie-restricted diets.² The metabolic slowdown appeared only when patients ate at maintenance calories. When they actively restricted calories, the weight loss trajectory was not blunted by the drug. This is a genuinely reassuring finding for anyone worried that sotalol will make dieting pointless.

When Weight Change Signals Something Else

Sotalol is used in a population with heart disease, and weight changes in that context are not always benign. A gain of more than two to three pounds in a single day, or more than five pounds in a week, can be an early sign of fluid overload from worsening heart failure. This is a medical concern, not a cosmetic one. Patients with heart failure are often told to weigh themselves daily and report rapid increases to their care team.

Other signs that weight gain on sotalol may be more than just a metabolic side effect include shortness of breath that worsens when lying flat, persistent ankle or leg swelling, and needing more pillows to sleep comfortably. These symptoms suggest the heart is not pumping effectively enough to keep fluid from pooling, and they require prompt evaluation rather than dietary adjustment.

On the flip side, unexplained weight loss on sotalol is also worth mentioning to your doctor. Uncontrolled arrhythmias, thyroid changes (beta-blockers can subtly affect thyroid hormone metabolism), and the underlying heart condition itself can all influence weight in either direction.

Sotalol Versus Other Antiarrhythmics for Weight-Conscious Patients

If weight gain is a significant concern, it helps to understand how sotalol stacks up against the alternatives. The main antiarrhythmic options for atrial fibrillation include flecainide, propafenone, dronedarone, dofetilide, and amiodarone. Of these, only sotalol and amiodarone have notable weight-related baggage, and for different reasons.

Amiodarone is known to affect the thyroid, causing either hypothyroidism (which promotes weight gain) or hyperthyroidism (which can cause weight loss). Its side-effect profile is far more complex than sotalol’s. Flecainide and dofetilide are not beta-blockers and do not share the metabolic-slowing mechanism. Propafenone has weak beta-blocking activity but far less than sotalol. For patients in whom several antiarrhythmics would be equally effective, the beta-blocking component of sotalol is a reasonable factor to weigh, though it rarely tips the decision on its own.

The review on antiarrhythmic use in obese patients found that sotalol was effective regardless of body weight and that its drug levels did not change meaningfully based on a patient’s size.³ That makes sotalol a reliable choice for people who are already overweight and need an antiarrhythmic. The drug works the same regardless of starting weight, which is not true of all medications in this class.

Why the Evidence Gap Exists

The reason sotalol-specific weight data is hard to find comes down to how the drug is studied. Clinical trials of sotalol focus on arrhythmia recurrence, QTc prolongation, proarrhythmia risk, and mortality. Weight is rarely a primary or even secondary endpoint. When trials do track weight, they usually report it as a baseline characteristic rather than an outcome. This creates a frustrating situation for patients asking a perfectly reasonable question: the drug has been on the market for decades, but no one has run a trial specifically designed to answer how much weight it causes people to gain.

The broader beta-blocker literature fills some of this gap, since the metabolic mechanisms are shared across the class. But extrapolating from propranolol or atenolol to sotalol is imperfect. Sotalol’s hydrophilic nature, its different receptor-binding profile, and the distinct patient population that uses it all introduce enough uncertainty that nobody should assume the weight effects are identical. The honest answer is that sotalol probably causes some weight gain in some people, the amount is likely modest, and the best available evidence is circumstantial rather than direct.